SAN DIEGO, May 28, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, released updated positive Phase 2 results of spevatamig (PT886) in combination with chemotherapy in frontline (1L)…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
